NEW YORK, Nov. 1 - Ciphergen Biosystems yesterday reported nearly two-fold growth in revenues and R&D spending during the third quarter amid a slightly widened net loss.
Revenues for the period ended Sept. 30 swelled to $10.2 million from $5.4 million one year ago.
R&D spending mirrored the revenue increase, jumping to $6.0 million from $3.3 million in the third quarter 2001.
As a result, net loss widened to $7.9 million, or $.29, from $6.9 million, or $.26, year over year, Ciphergen said.
The company said it had $51.6 million a year in cash, cash equivalents, and investments in securities as of Sept. 30.
Click here for more information.